Bionomics Inc.

Merck Sharp + Dohme Corp.

Laurent Schaeffer

Dharam Paul

Rajinder Singh

Christophe Morice

Bruno Giethlen

Andrew John Harvey

Justin Ripper

Belinda C Huff

Hamish Toop

Thomas Avery

Patrick Bazzini

Jean-Marie Contreras

Christophe Joseph

Ian M Bell

Brendan M Crowley

Kenneth J Leavitt

Fabrice Garrido

Lorna Helen Mitchell

Florence Chery

Audrey Fluck

Erin Smith

Celine Michaut-Simon

Mathieu Michaut

Aurelie Fromeyer

The present invention relates generally to chemical compounds of formula (I) and methods for their use and preparation. In particular, the invention relates to chemical compounds which are useful in relation to the treatment of diseases, disorders or conditions which would benefit from the modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR), such as anxiety, depression and stress related disorders.

Cyclic compounds as receptor modulating therapeutics and methods and uses thereof

Activators of Kv3.1 and/or Kv3.2 channels which are therapeutically useful in the treatment of cognitive dysfunction and the negative symptoms which are associated with central nervous system disorders such as schizophrenia, Alzheimer's disease, Tourette's syndrome, autism, dementia, epilepsy and other disorders where gamma oscillations are dysfunctional are provided. The activators include substituted N-heteroaryl compounds.

Substituted-N-heteroaryl compounds and uses thereof

Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein 'R', 'R', &#x201c;R&#x201d;, &#x201c;R&#x201d;, &#x201c;R&#x201d;, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (&#x3b1;7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof

The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (&#x3b1;7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of &#x3b1;7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases. 

Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I

The present invention relates to compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (&#x3b1;7nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of &#x3b1;7nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also inflammatory diseases.

Positive allosteric modulators of the &#x3b1;7 nicotinic acetylcholine receptor and uses thereof

Growing community of inventors

Illkirch, France

Laurent Schaeffer